OSELTAMIVIR AS ANTIVIRAL THERAPY OF INFLUENZA A(H1N1)pdm09 IN CHILDREN AND ADULTS

In this article are presented the results of comparative of experimental (on cell cultures) study of the influenza virus strains sensitivity to neuraminidase  inhibitor — Oseltamivir and blocker of M-canal — Rimantadin аnd the results of study effectiveness of the inclusion in the complex therapy of...

Full description

Bibliographic Details
Main Authors: L. V. Osidak, V. V. Zarubaev, O. I. Afanasyeva, L. V. Voloshuk, V. V. Gonchar, М. М. Pisareva, E. G. Golovacheva, E. А. Dondurey, V. S. Afanasyeva, V. F. Suhovetskaya, E. V. Obraztsova, E. G. Rozhkova, А. Gо, V. M. Guseva, A. A. Shtro, N. Y. Kaika
Format: Article
Language:Russian
Published: LLC "Diagnostics and Vaccines" 2016-09-01
Series:Детские инфекции (Москва)
Subjects:
Online Access:https://detinf.elpub.ru/jour/article/view/241
Description
Summary:In this article are presented the results of comparative of experimental (on cell cultures) study of the influenza virus strains sensitivity to neuraminidase  inhibitor — Oseltamivir and blocker of M-canal — Rimantadin аnd the results of study effectiveness of the inclusion in the complex therapy of 331 hospitalized patients (children and adults) rapy of А(Н1N1)pdm09 antiviral drug — inhibitor of neuraminidase Oseltamivir that occurred during the epidemic seasons 2009—2010 and 2015—2016  in terms of observational clinical studies.  It is shown that this drug, can be successfully used in the treatment of children and adults with influenza А(Н1N1)pdm09 during 8—9 years after beginning of pandemic cycle.
ISSN:2072-8107